Loading...Loading...The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practice will meet this week to consider and recommend who should get respiratory syncytial virus (RSV), influenza, and COVID-19 vaccines.In the presentation slides to the U.S. agency, Moderna Inc MRNA shared safety set data, with a cut-off date of March 8, 2024, based on the median of 18.8 months of follow-up.The data showed that vaccine efficacy fell to around 50% after 18 months on participants aged 60 ...